Crospovidone DC Granules are pharmaceutical excipient granules based on cross-linked polyvinylpyrrolidone, also known as cross-linked PVP, polyvinylpolypyrrolidone (PVPP), and crospovidone. Crospovidone is a water-insoluble synthetic cross-linked homopolymer of N-vinyl-2-pyrrolidone with CAS Number 9003-39-8 and polymeric formula (C₆H₉NO)ₙ. The current USP-NF monograph specifies a nitrogen content of 11.0%–12.8% on the dried basis and recognizes Type A and Type B grades according to particle size.
Crospovidone DC Granules are a granulated form of cross-linked polyvinylpyrrolidone designed for use in pharmaceutical formulation processes involving direct compression (DC) or other controlled powder-processing operations, where appropriate. The DC designation should refer to the actual product's intended processing characteristics and approved specification rather than being assumed solely from the chemical identity of crospovidone.
Crospovidone is primarily used as a superdisintegrant in oral solid formulations. Because the polymer is cross-linked and insoluble in water, it can absorb and draw liquid into a formulation without dissolving into a viscous solution. This characteristic supports rapid breakup of tablets when the excipient is appropriately incorporated into the formulation.
Direct compression requires excipients with suitable physical characteristics for blending, powder movement, die filling and tablet formation. Particle engineering can influence flow, packing, compressibility and content uniformity. Therefore, a DC-grade crospovidone granule product should be evaluated according to its actual particle-size distribution, bulk density, flow characteristics, moisture level and compaction behavior.
The term DC Granules can therefore be used to position the product for direct-compression formulation applications, while numerical functional specifications such as D10, D50, D90, bulk density, tapped density or Hausner ratio should be stated only when they are part of the approved product specification.
Crospovidone is used as a disintegrant in oral solid dosage-form development. Its cross-linked structure provides water uptake and swelling characteristics that can assist the breakup of a compressed formulation.
Unlike soluble povidone grades, crospovidone is specifically cross-linked and water-insoluble. USP defines it as a water-insoluble synthetic cross-linked homopolymer of N-vinyl-2-pyrrolidone.
This distinction is important when selecting an excipient for a formulation because povidone and crospovidone are not interchangeable simply because they share the same base monomer.
Crospovidone DC Granules can be evaluated for several physical and functional characteristics during formulation development, including:
For a commercial pharmaceutical excipient, these properties should be controlled through the manufacturer's approved specification and certificate of analysis.
USP also recognizes different crospovidone types based on particle size, making particle-size control an important characteristic of the material.
Crospovidone DC Granules may be considered for formulations where a granulated excipient format is preferred for powder handling and direct-compression processing. Direct compression involves blending formulation components followed by compression without a conventional wet-granulation step.
The suitability of a crospovidone granule grade depends on the complete formulation. Factors such as active ingredient loading, diluent selection, lubricant concentration, compression force, tooling, tablet size and processing conditions can affect final tablet performance.
For this reason, the recommended concentration and processing conditions should be established during formulation development rather than applying a universal concentration to every formulation.
Crospovidone offers several properties relevant to oral solid formulation development:
Water Insolubility: Crospovidone is water-insoluble, which distinguishes it from soluble povidone.
Cross-Linked Structure: The cross-linked polymer structure supports its function as a superdisintegrant.
Granulated Format: A granulated presentation can be useful when particle handling and powder-processing characteristics are important.
Direct Compression Application: DC-grade material can be evaluated for direct-compression formulations according to its actual functional specifications.
Pharmaceutical Excipient: Crospovidone is established as a pharmaceutical excipient for oral solid dosage-form development.
Crospovidone is described in the USP-NF as 1-ethenyl-2-pyrrolidinone homopolymer / 1-vinyl-2-pyrrolidinone homopolymer, CAS 9003-39-8. The USP definition specifies nitrogen content of 11.0%–12.8% calculated on the dried basis.
Quality evaluation may include identification, nitrogen content, moisture-related testing, residue on ignition, impurities and other applicable pharmacopoeial requirements. USP documentation also identifies heavy metals as lead with a limit of NMT 10 ppm in the harmonized Crospovidone material.
Where a product is marketed as USP/NF, BP or Ph. Eur. compliant, the claim should correspond to the actual grade and current applicable specification.
Crospovidone DC Granules can be considered for pharmaceutical formulation applications such as:
The final performance depends on the formulation composition and manufacturing process.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 0.5% |
| Residue on Ignition | NMT 0.1% |
| pH (1% Solution) | 2.0 – 4.0 |
| Individual Impurity | NMT 1.0% |
| Water Content | NMT 0.5% |